Loading
A phase 2 trial of SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab in biliary tract cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., active and no longer recruiting.
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer is a phase 2 interventional study registered as NCT06465563 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 93 participants enrolled, started 2024-07-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: SHR-8068, Adebrelimab, Cisplatin, Gemcitabine and Bevacizumab Injection.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Bevacizumab and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Cisplatin, Monoclonal antibodies and the tag pipeline.
Shares SHR-8068, Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares Adebrelimab, Jiangsu Hengrui Pharmaceuticals, Gemcitabine, Cisplatin and the tag pipeline.